Abstracts on all presentations and poster appearing on this page are published in the conference programme.
The winner of the £300 prize for best conference poster presentation, kindly donated by Wyeth Vaccines, was Bridget Gollan from the Department of Microbiology, Centre of Molecular Microbiology and Infection, Imperial College, London.
| Identification and characterisation of meningococcal strains that are resistant to serum bactericidal activity elicited by the meningococcal conjugate C Vaccine |
Bridget Gollan, Maria-Jose Gonzalez and Chris M Tang
Department of Microbiology, Centre of Molecular Microbiology and Infection, Imperial College, London |
0.46mb |
| Randomised controlled trial and dose finding study of glycerol adjuvant therapy in adult bacterial meningitis in Malawi |
Ajdukiewicz KMB1,2, Cartwright K1, Molyneux ME3, Zijlstra EE1,Lalloo DG4 .
1Dept of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi; 2Dept of Tropical Medicine, Hospital for Tropical Diseases, London, UK.; 3 Malawi-Liverpool-Wellcome Trust, Blantyre, Malawi; 4Liverpool School of Tropical Medicine, Liverpool, UK . |
0.9mb |
| Human transferrins and their bacterial receptors: identification of regions involved in receptor – ligand interactions in Neisseria meningitidis |
Maryam Amini1, Sebastien Farnaud2, Andrew R Gorringe3 and Robert W Evans1
1Nutritional Sciences Division, Guy’s Campus, King’s College London, SE1 1UL, UK; 2School of Biosciences, University of Westminster, London W1W 6UW, UK; 3Health Protection Agency (HPA), Porton Down, Salisbury, SP4 0JG, UK |
0.78mb |
| Haemophilus influenzae invasive infection in Portugal: 1999-2006 |
P Bajanca1, D Louro1, M Caniça1 and the ARSIP (Antibiotic Resistance Surveillance Programme in Portugal)
1Antibiotic Resistance Unit, Bacteriology Department, National Institute of Health, Lisbon, Portugal |
0.75mb |
| L. monocytogenes meningitis in a child with juvenile idiopathic arthritis treated with a TNF-alpha antagonist |
Banks J1, Ladhani S1, Hambly M2, Bate T2, Chakraborty R1
1Department of Infectious Diseases, St. George’s Hospital, Blackshaw Rd, London SW17 OQT, England : 2 Department of Paediatrics, Epsom General Hospital, Dorking Rd, Epsom, Surrey, KT18 7EG, England |
0.14mb |
| Burden of meningococcal disease in older adults, United States 1995-2004 |
Kimberly Cushing1, Amanda Cohn1, Leonard Mayer1, David Stephens2, Joan Baumbach3, Nancy Bennett4, Allen Craig5, Ken Gershman6, Lee Harrison7, Jim Hadler8, Ruth Lynfield9, Art Reingold10, Ann Thomas11, and Thomas Clark1
1National Center for Immunisation and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia,USA, 2Georgia Emerging Infections Program (EIP), 3New Mexico EIP, 4New York EIP, 5Tennessee EIP, 6Colorado EIP, 7Maryland EIP,8Connecticut EIP, 9Minnesota EIP, 10California EIP, 11Oregon Public Health Division, USA |
0.23mb |
| Characterisation of the memory B-cell responses to conjugate vaccination |
E Clarke1, N Williams1, R Heyderman1,2, A Finn1
1Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, University Walk, Bristol, BS8 1TD, UK. 2Malawi-Liverpool-Wellcome Trust, Clinical Research Programme, PO Box 30096, Chichiri, Blantyre 3, Malawi. |
0.05mb |
| Evidence of genetic structuring among meningococcal strains isolated before and after mass immunisation in Cuba |
Climent Y.1,2, Martinez I1, Daniel Y1,2, Maiden MCJ3, Sotolongo F1, Urwin R4
1Finlay Institute, Serum and Vaccines Production Center, Habana, Cuba. 2Center for Genetic Engineering and Biotechnology, Habana,Cuba. 3Peter Medawar Building for Pathogen Research and Department of Zoology, University of Oxford, UK. 4Department of Biology, Pennsylvania State University, University Park. |
0.11mb |
| Burden of meningococcal disease in the United States prior to implementation of meningococcal conjugate vaccine, 1996-2005 |
Amanda Cohn1, Kimberly Cushing1, Elizabeth Zell1, Leonard Mayer1, Kathryn Arnold2, Joan Baumbach3, Nancy Bennett4, Allen Craig5, Ken Gershman6, Lee Harrison7, Jim Hadler8, Ruth Lynfield9, Art Reingold10, Ann Thomas11, and Thomas Clark1
1National Center for Immunisation and Respiratory Diseases (proposed), Centers for Disease Control and Prevention (CDC), Atlanta,Georgia, USA, 2Georgia Emerging Infections Program (EIP), 3New Mexico EIP, 4New York EIP, 5Tennessee EIP, 6Colorado EIP, 7Maryland EIP, 8Connecticut EIP, 9Minnesota EIP, 10California EIP, 11Oregon Public Health Division |
0.23mb |
| Epidemiology of culture-confirmed meningococcal disease in Pernambuco, Brazil |
Zenize Rocha da Silva Costa 1,2, Zelma de Fátima Chaves Pessôa1,3, Maria do Carmo Menezes Bezerra Duarte3, Eliane Mendes Germano3, Valdelucia Oliveira Cavalcanti4, Jailson de Barros Correia2,3
1Health Surveillance Department, Pernambuco State Secretary of Health, 2University of Pernambuco, 3Professor Fernando FigueiraInstitute of Mother and Child Health, 4Bacteriology Section, Milton Bezerra Sobral Central Laboratory of Pernambuco |
0.15mb |
| Missed opportunities for early treatment of meningococcal disease in Brazil |
Lucas Victor Alves 1,2, Maria do Carmo Menezes Bezerra Duarte2, Rebeca Evangelista Pessoa1, Nancy de Barros Correia2, Maria Eulália M Corte Real3, Jailson de Barros Correia1,2
1University of Pernambuco, 2Professor Fernando Figueira Institute of Mother and Child Health, 3Correia Picanço Hospital |
0.11mb |
| Induction of protective serum meningococcal bacterial neutralising antibodies and mucosal immunoglobulin A in human volunteers immunised intranasally |
Huo Z1, Sinha R1, McNeela EA2, Borrow R3, Giemza R1, Cosgrove CA1, Heath PT1, Mills KH2, Rappuoli R4, Griffin GE1, Lewis DJM1
1St George’s Vaccine Institute, London, UK; 2Immune Regulation Research Group, Department of Biochemistry, Trinity College, Dublin, Ireland; 3Vaccine Evaluation Department, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK; and 4Novartis Vaccines, Via Fiorentina, Siena, Italy |
0.3mb |
| Endotoxaemia in paediatric critical illness |
Shamik Dholakia, Helen Betts, Simon Nadel
St Mary’s Hospital and Imperial College London |
0.9mb |
| A review of the administration of benzylpenicilllin for meningococcal disease by qualified ambulance staff in a high incidence area |
Debra Khan1, Huda Mohamed1 and Madhu Bardhan1, Mathew Wyse2, Andrew Butters2, Louise Dyke1
1Coventry and Warwickshire Health Protection Unit, 2Coventry and Warwickshire Ambulance Trust |
4.91mb |
| Progress toward the prevention of childhood pneumonia and meningitis – The Hib Initiative |
Karen Edmond for the Hib Initiative
Dr Karen Edmond, FRCPCH PhD, Senior Lecturer, London School of Hygiene and Tropical Medicine; Honorary Consultant Paediatrician, University College London Hospitals; and Epidemiologist, The Hib Initiative. The Hib Initiative is comprised of four organisations: Johns Hopkins Bloomberg School of Public Health, London School of Hygiene and Tropical Medicine, World Health Organization and Centers for Disease Control and Prevention. |
3.15mb |
| Immunogenicity of three (0, 12 and 60 weeks) or four (0, 6, 12 and 60 weeks) doses of the meningococcal serogroup B outer membrane vesicle vaccine MeNZBTM when administered to healthy adults |
Jamie Findlow1, Ann Holland1, Rita Barchha1, Nick Hamer1, Paul Balmer1, Jo Southern2, Robert Read3, Phillip Oster4, Ray Borrow1, Liz Miller2.
1Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ, UK; 2Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London, NW9 5EQ, UK; 3Academic Unit of Infection and Immunity, School of Medical and Biomedical Sciences, University of Sheffield, Beech Hill Road, S10 2RX, UK; 4Novartis Vaccines, Via Fiorentina 1, 53100, Siena, Italy. |
0.19mb |
| Age-stratified prevalence of pneumococcal serotype-specific IgG in England and its relationship to serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7 valent conjugate vaccine |
Sarah Frankland1, Paul Balmer1, Ray Borrow1, Jamie Findlow1, Rosalind Warrington1, Pauline Waight2, Robert George3, Nick Andrews4, Elizabeth Miller2
1Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, UK; 2Immunisation Division, Centre for Infections, Health Protection Agency, Colindale, London, UK; 3Respiratory and Systemic Infections Laboratory, Centre for Infections, Health Protection Agency, Colindale, London, UK; 4Statistics Unit, Centre for Infections, Health Protection Agency, Colindale, London, UK. |
0.27mb |
| Serotype distribution and clinical presentation of pneumococcal meningitis in Denmark, 2000-2005 |
Harboe ZB1, Benfield T2, Valentiner-Branth P3, Howitz M3, Christensen JJ1, Kaltoft M1, Lambertsen L1, Krogfelt KA 1, Konradsen HB1.
1Department of Bacteriology, Mycology and Parasitology, Division of Microbiology and Diagnostics, Statens Serum Institut; 2Department of Epidemiology, Division of Epidemiology, Statens Serum Institut; 3Department of Infectious Diseases, Hvidovre University Hospital; 4Department of Epidemiology Research, Division of Epidemiology, Statens Serum Institut |
0.07mb |
| The role of LPS in meningococcal septic disease studied in a porcine model using wild-type and an LPS-free mutant of N. meningitidis |
Hellerud BC1,3, Nielsen EW2, Thorgersen EB3, Castellheim A3, Mollnes TE2,3, Brandtzaeg P1
1Dept. of Paediatrics, Ullevaal University Hospital, and University of Oslo, Norway 2Nordland Hospital, Bodoe, and University of Tromsoe, Norway, 3Institute of Immunology, Rikshospitalet, and University of Oslo, Norway. |
0.14mb |
| Risk of adverse birth outcome after group B meningococcal disease: Two population based cohort studies |
Michael Howitz 1, Jacob Brunbjerg Simonsen2, Tyra Grove Krause1, John Robbins3, Rachel Schneerson3, Kåre Mølbak1, Mark A. Miller4
1Department of Epidemiology, Statens Serum Institut, Copenhagen, Denmark; 2Department of Epidemiology Research, Statens SerumInstitut, Copenhagen, Denmark; 3Laboratory of Developmental and Population Studies, National Institute of Child Health and Human Development, Bethesda, USA; 4Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, USA |
0.18mb |
| Antimicrobial susceptibility patterns of Polish invasive isolates of Neisseria meningitidis in the years 1997-2006 |
Marcin Kadlubowski1, Anna Skoczyñska1, Tomasz Wolkowicz2, Waleria Hryniewicz1
1National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland; 2Department of Bacterial Genetics, Institute of Microbiology, Faculty of Biology, Warsaw University, Warsaw, Poland |
0.87mb |
| Mechanisms of meningitis-associated labyrinthitis and hearing impairment |
Matthias Klein, Barbara Angele, Uwe Koedel, and Hans-Walter Pfister
Department of Neurology, Ludwig-Maximilians-University, Munich, Germany |
1.14mb |
| A proactive, multi-partner approach to communications leads to a significant increase in media coverage surrounding pneumococcal disease |
Kvist H1, Haylock S 2, Guibeleguiet C3
1Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 2Global Health & Development Unit, Ruder Finn, London, UK; 3Healthcare Practice, Echo Research, Godalming, Surrey, UK |
0.21mb |
| Structural characterisation and antibody response of a recombinant protein vaccine against N. meningitidis |
A Martino1, C Magagnoli3, G De Conciliis3, S D’Ascenzi3, D Crane1, H Chan1, I. M Feavers1, M Forster2, B Bolgiano1
1Division of Bacteriology, National Institute for Biological Standards and Control, Potters Bar, Herts, UK; 2Information Systems, Syngenta, Jealott’s Hill International Research Centre, Bracknell, Berkshire, UK; 3Technology Development Dept., Novartis Vaccines and Diagnostics, Siena, Italy. |
0.98mb |
| Evaluation of clinical batches of MenAfriVac, a conjugate vaccine against meningococcal group A disease |
C Mattick, A Martino, IM Feavers, K Burkin, B Bolgiano
Division of Bacteriology, National Institute for Biological Standards and Control, South Potters Bar, Herts, EN6 3QG United Kingdom |
0.49mb |
| Probing differences in gene expression in human monocytes (hMo) induced by wild-type Neisseria meningitides (Nm) versus a lipopolysaccharide deficient Nm |
Reidun Øvstebø1, Berit Brusletto1, Ole Kristoffer Olstad1, Kari Bente Foss Haug1, Petter Brandtzaeg2, Peter Kierulf1 .
R&D, 1Departments of Clinical Chemistry and 2Pediatrics, Ullevål University Hospital, Oslo, Norway. |
0.17mb |
| Microcirculatory dysfunction in children with severe meningococcal disease using Orthogonal Polarization Spectral Imaging |
Fauzia Paize1, Nick Makwana1, Enitan Carrol1, Paul Baines2, Andrew Riordan2, Richard Sarginson2, Alistair Thomson1, CA Hart3
1Institute of Child Health, University of Liverpool, UK; 2Royal Liverpool Children’s Hospital, Liverpool, UK; 3Medical Microbiology, University of Liverpool, UK |
0.33mb |
| Effect of the introduction of the Pneumococcal Conjugate Vaccine in the UK childhood immunisation scheme on the genetic structure of paediatric invasive pneumococci |
Bruno Pichon1, Laura Beasley1, Mary Slack1, Androulla Efstratiou1, Elisabeth Miller2 and Robert George1
1Respiratory and Systemic Infection Laboratory, HPA – Centre for Infection, London, UK, 2Immunisation Department, HPA – Centre for Infection, London, UK. |
0.23mb |
| Regulation of a novel TonB dependent receptor system in N. Meningitidis required for intracellular replication |
Paola Quattroni, Megan Winterbotham, Thomas Sutherland, Rachel Exley and Christoph Tang
Department of Microbiology, Centre for Molecular Microbiology and Infection, Imperial College London, SW7 2AZ, UK |
0.88mb |
| Genotypic characterisation of serogroup B meningococci in healthy carriers in Scotland (1996-2003) – implications for vaccine design |
KJ Scott1,2, J Jefferies1, TJ Mitchell2, GFS Edwards1, E Muros-Le Rouzic3 and MA Diggle1
1Scottish Meningococcus and Pneumococcus Reference Laboratory (SMPRL), Dept of Microbiology, Stobhill Hospital, Glasgow, UK; 2Division of Infection and Immunity, Faculty of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK; 3Sanofi Pasteur SA, Lyon, France |
0.08mb |
| Prospective study of childhood bacterial meningitis in Katmandu, Nepal |
Shah AS1, Knoll MD2, Sharma PR1, Kulkarni P2, Lalitha MK3, Thomas K3, Steinhoff M2.
1Institute of Medicine and Kanti Children Hospital, Kathmandu, Nepal; 2Johns Hopkins School of Public Health, Baltimore, USA; 3Christian Medical College Vellore, India |
0.12mb |
| Immune response to pneumococcal conjugate vaccination in asplenic individuals |
Elaine Stanford1, Fiona Print2, Michelle Falconer3, Kenneth Lamden2, Samuel Ghebrehewet3, Nick Phin3, David Baxter4, Matthew Helbert5, Nick Andrews6, Paul Balmer1, Raymond Borrow1, Edward Kaczmarski1
1Health Protection Agency North West, Manchester Royal Infirmary; 2Cumbria & Lancashire Health Protection Unit, Ormskirk and District General Hospital, Lancashire; 3Cheshire and Merseyside Health Protection Team, Chester Microbiology Laboratory, Chester;4Infection Control Unit, Stockport; 5Department of Immunology, Manchester Royal Infirmary; 6Health Protection Agency, Centre for Infections, London |
0.29mb |
| Prevalence of ST-23 complex among serogroup Y meningococci isolated from recent cases of meningitis and septicaemia in Italy |
Paola Stefanelli, Cecilia Fazio, Arianna Neri, Tonino Sofia, Paola Mastrantonio
Dept. Infectious, Parasitic and Immune-mediated Diseases-Istituto Superiore di Sanità, Rome, Italy |
0.25mb |
| Differential induction of innate immune responses following interaction of pathogenic and commensal Neisseria spp. with nasopharyngeal epithelial cells |
Tezera LB, Jackson S, Davenport V
Faculty of Applied Sciences, University of the West of England, Bristol, UK |
0.27mb |
| Mucosal immunity to Neisseria lactamica and the development of cross-reactive T-cell memory to Neisseria meningitidis |
AT Vaughan1, A Gorringe2, CV Davenport3, NA Williams1 and RS Heyderman1,4
1Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, UK; 2Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK; 3Faculty of Applied Sciences, University of the West of England, Bristol, UK; 4Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Chichiri, Blantyre, Malawi. |
0.11mb |
| Epidemiology and molecular characteristics of carried meningococci in epidemic versus non-epidemic situations in western Burkina Faso |
Mueller JE1, Njanpop-Lafourcade BM1, Drabo A2, Yaro S2, Sanou O1, Tarnagda Z3, Sangaré L4, Traoré Y5, Diagbouga S2, Koeck JL6, Borrow R7, Nicolas P8, Gessner BD1
1Agence de Médecine Préventive, Paris, France; 2Centre Muraz, Bobo-Dioulasso, Burkina Faso; 3Institut de Recherche en Science de la Santé (IRSS), Bobo-Dioulasso ; 4Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou; 5Université de Ouagadougou, Ouagadougou, Burkina Faso; 6Hôpital d’Instruction des Armées Robert Picqué Bordeaux, France; 7Vaccine Evaluation Unit, Health Protection Agency, Manchester, United Kingdom; 8WHO Collaborating Center for Reference and Research on Meningococci, Marseille, France. |
0.32mb |
| Lessons learned after application of the Expression Library Immunisation screening protocol to Neisseria meningitidis serogroup B |
Daniel Yero1,2, Sonia González2, Mildrey Fariñas1, Evelín Caballero2, Karem Cobas2, Daiyana Díaz1, Yusleydis Pérez2, Yanet Climent1,2, Yamilé López1, Rosa L Solis1, Armando Acosta1, Charlotte Brookes3, Stephen Taylor3, Andrew Gorringe3.
1Department of Molecular Biology. Cuba; 2Meningococcal Research Department, Center for Genetic Engineering and Biotechnology, Cuba; 3Health Protection Agency, Centre for Emergency Preparedness and Response, Porton Down, Salisbury, UK |
0.14mb |